Definitive Healthcare Corp. (DH)
NASDAQ: DH · Real-Time Price · USD
2.710
+0.100 (3.83%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Definitive Healthcare Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Definitive Healthcare stock have an average target of 5.35, with a low estimate of 3.00 and a high estimate of 8.00. The average target predicts an increase of 97.42% from the current stock price of 2.71.
Analyst Consensus: Hold
* Price targets were last updated on Mar 4, 2025.
Analyst Ratings
The average analyst rating for Definitive Healthcare stock from 11 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 7 | 8 | 7 | 7 | 7 | 7 |
| Sell | 1 | 1 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $4.5 → $3 | Hold | Maintains | $4.5 → $3 | +10.70% | Mar 4, 2025 |
| Barclays | Barclays | Sell Maintains $4 → $3 | Sell | Maintains | $4 → $3 | +10.70% | Mar 3, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 16, 2025 |
| Barclays | Barclays | Hold → Sell Downgrades $4 | Hold → Sell | Downgrades | $4 | +47.60% | Jan 13, 2025 |
| Stephens & Co. | Stephens & Co. | Hold Initiates $5 | Hold | Initiates | $5 | +84.50% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
241.31M
from 252.20M
Decreased by -4.32%
Revenue Next Year
248.08M
from 241.31M
Increased by 2.81%
EPS This Year
0.22
from -3.54
EPS Next Year
0.26
from 0.22
Increased by 18.98%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 247.4M | 267.1M | 284.1M |
| Avg | 241.3M | 248.1M | 261.0M |
| Low | 221.7M | 214.8M | 236.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.9% | 10.7% | 14.5% |
| Avg | -4.3% | 2.8% | 5.2% |
| Low | -12.1% | -11.0% | -4.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.28 | 0.40 | 0.46 |
| Avg | 0.22 | 0.26 | 0.31 |
| Low | 0.18 | 0.20 | 0.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 81.9% | 77.1% |
| Avg | - | 19.0% | 20.4% |
| Low | - | -10.6% | -24.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.